Adenosine A(2A) antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys

Annals of Neurology

Volumn 43, Issue 4, 1998, Pages 507-513

  Kanda, Tomoyuki ^a,b   Jackson, Michael J ^a   Smith, Lance A ^a   Pearce, Ronald K B ^a   Nakamura, Joji ^b   Kase, Hiroshi ^b   Kuwana, Yoshihisa ^a,b   Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 8 [2 (3,4 DIMETHOXYPHENYL)ETHENYL] 1,3 DIETHYL 2,7 DIYDRO 7 METHYL 1H PURINE 2,6 DIONE; ADENOSINE A2A RECEPTOR ANTAGONIST; ISTRADEFYLLINE; LEVODOPA; UNCLASSIFIED DRUG; ADENOSINE A2A RECEPTOR; ADENOSINE RECEPTOR; ANTIPARKINSON AGENT; BENSERAZIDE; PURINE DERIVATIVE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DYSKINESIA; FEMALE; LOCOMOTION; MALE; MARMOSET; MOTOR DYSFUNCTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; ANALYSIS OF VARIANCE; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; STEREOTYPY; TIME;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; BENSERAZIDE; CALLITHRIX; FEMALE; MALE; MOTOR ACTIVITY; PARKINSON DISEASE, SECONDARY; PURINES; RECEPTOR, ADENOSINE A2A; RECEPTORS, PURINERGIC P1; STEREOTYPED BEHAVIOR; TIME FACTORS;

EID: 0031594271     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410430415     Document Type: Article

References (32)

1. Nutt JG. Levodopa-induced dyskinesia. Neurology 1990:40: 340-345
2. Quinn N, Critchley P, Maren CD. Young onset Parkinson's disease. Move Disord 1987;2:73-91
3. 2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol Sci 1997;18:338-344
4. Daly JW, Butts-Lamb P, Padgett W. Subclasses of adenosine receptors in the central nervous system: interaction with caffeine and related methylxanthines. Cell Mol Neurobiol 1983;3: 69-74
5. Bruns RF, Lu GH, Pugsley TA. Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes. Mol Pharmacol 1986;29:331-346
6. Fredholm BB, Abbracchio MP, Burnstock G, et al. Nomenclature and classification of purinoceptor. Pharmacol Rev 1994;46: 143-156
7. Jarvis MF, Williams M. Direct auroradiographic localization of adenosine A2 receptors in the rat brain using the A2-selective agonist [3H]CGS 21680. Eur J Pharmacol 1991;168:243-246
8. Schiffmann SN, Libert F, Vassart G, Vanderhaeghen J-J. Distribution of adenosine A2 receptor mRNA in the human brain. Neurosci Lett 1989;130:177-181
9. Schiffmann SN, Jacobs O, Vanderhaeghen J-J. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: An in situ hybridization histochemistry study. J Neurochem 1991;57:1062-1067
10. Ferre S, Rubio A, Fuxe K. Stimulation of adenosine A2 receptors induces catalepsy. Neurosci Lett 1991;130:162-164
11. Kanda T, Shiozaki S, Schimada J, et al. KF17837: a novel selective adenosine A2a receptor antagonist with anticataleptic activity. Eur J Pharmacol 1994;256:263-268
12. Fuxe K, Ungerstedt U. Action of caffeine and theophylline on supersensitive dopamine receptors: considerable enhancement of receptor response to treatment with DOPA and dopamine receptor agonists. Med Biol 1974;52:48-54
13. Brown SJ, Gill R, Evenden JL, et al. Striatal A2 receptor regulates apomorphine-induced turning in rats with unilateral dopamine denervation. Psychopharmacology 1991;103:78-82
14. Josselyn SA, Beninger RJ. Behavioral effects of intrastriatal caffeine mediated by adenosinergic modulation of dopamine. Pharmacol Biochem Behav 1991;39:97-103
15. Velluci SV, Sirinathsinghji DJS, Richardson PJ. Adenosine A2 receptor regulation of apomorphine-induced turning in rats with unilateral striatal dopamine denervation. Psychopharmacology 1993;111:383-388
16. Shimada J, Suzuki F, Nonaka H, et al. (E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl) xanthines: potent and selective adenosine A2 antagonists. J Med Chem 1992;35:2342-2345
17. Nonaka H, Ichimura M, Takeda M, et al. KF17837((E)-8-(3,4-dimethoxystyryl) 1,3-dipropyl-7-methylxanthine), a potent and selective adenosine A2 receptor antagonist. Eur J Pharmacol 1994;267:335-341
18. Shimada J, Koike N, Nonaka H, et al. (E)-1,3-Diethyl-8-(3,4-dimethoxystyryl)-7-methlxanthine: a potent adenosine A2 antagonist with anti-cataleptic activity. Bioorg Med Chem Lett 1997;7:2349-2352
19. Loschmann PA, Smith LA, Lange KW, et al. Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP treated common marmosets. Psychopharmacology 1992;109:49-56
20. Pearce RKB, Jackson M, Smith L, et al. Chronic L-dopa administration induces dyskinesia in the MPTP-treated common marmoset (Callithrix jacchus). Move Disord 1995;10:731-740
21. Akai T, Yamaguchi M, Mizuta E, Kuno S. Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys. Ann Neurol 1993;33:507-511
22. Calon F, Goulet M, Blanchet PJ, et al. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAa receptors in the striatopallidal complex. Brain Res 1995;680:43-52
23. Martines-Mir MI, Probst A, Palacios JM. Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease. Neuroscience 1991;42:697-706
24. Kurokawa M, Kirk IP, Kirkpatrik A, et al. Inhibition by KF17837 of adenosine A2a receptor-mediated modulation of striatal GABA and ACh release. Br J Pharmacol 1994;113: 43-48
25. Mori A, Shindou T, Ichimura M, et al. The role of adenosine A2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. J Neurosci 1996;16:605-611
26. Kurokawa M, Koga K, Kase H, et al. Adenosine A2a receptor-mediated modulation of striatal actylcholine release in vivo. J Neurochem 1996;66:1882-1888
27. Mouradian MM, Heuser IJE, Baronti F, et al. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989;25:523-526
28. Blanchet P, Bedard PJ, Britton DR, Kebabian JW. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine-exposed monkeys. J Pharmacol Exp Ther 1993;267:275-279
29. Blanchet PJ, Grondin R, Bedard PJ. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. Move Disord 1996;11:91-94
30. Balanchet PJ, Gomez-Mancilla B, Di Paolo T, Bedard PJ. Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia? Fundam Clin Pharmacol 1995;9: 434-442
31. Kawaguchi Y, Wilson CJ, Augood SJ, Emson PC. Striatal interneurons: chemical, physiological and morphological characterization. Trends Neurosci 1995;18:527-535
32. Maliy J, Stone TW. The effect of theophylline on parkinsonian symptoms. J Pharm Pharmacol 1994;46:515-517